<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02088528</url>
  </required_header>
  <id_info>
    <org_study_id>TCEC 044/13-14</org_study_id>
    <nct_id>NCT02088528</nct_id>
  </id_info>
  <brief_title>The Ghana Primary Tube Versus Trabeculectomy Study</brief_title>
  <acronym>GPTVT</acronym>
  <official_title>The Ghana Primary Tube Versus Trabeculectomy Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tema Christian Eye Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>International Glaucoma Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>HCA International Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Tema Christian Eye Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Medical treatment of glaucoma in West Africa is often unsuccessful because of the cost of&#xD;
      medications, disease severity and poor compliance. Surgical treatment is likely to be a more&#xD;
      practical solution.&#xD;
&#xD;
      The purpose of this study is to compare the safety and efficacy of the Aurolab glaucoma&#xD;
      drainage device against trabeculectomy with mitomycin-c in a prospective randomised surgical&#xD;
      study.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2014</start_date>
  <primary_completion_date type="Anticipated">March 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in intraocular pressure</measure>
    <time_frame>3 months, 6 months, 1 year, 18 months, 2 years, 2½ years, 3 years, 3½ years, 4 years, 4½ years, 5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complication rates</measure>
    <time_frame>1 day, 1 week, 1 month, 3 months, 6 months, 1 year, 18 months, 2 years, 2½ years, 3 years, 3½ years, 4 years, 4½ years, 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual acuity</measure>
    <time_frame>1 day, 1 week, 1 month, 3 months, 6 months, 1 year, 18 months, 2 years, 2½ years, 3 years, 3½ years, 4 years, 4½ years, 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual field</measure>
    <time_frame>6 months, 1 year, 2 years, 3 years, 4 years, 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reoperation for glaucoma</measure>
    <time_frame>1 day, 1 week, 1 month, 3 months, 6 months, 1 year, 18 months, 2 years, 2½ years, 3 years, 3½ years, 4 years, 4½ years, 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Supplemental medical therapy</measure>
    <time_frame>1 day, 1 week, 1 month, 3 months, 6 months, 1 year, 18 months, 2 years, 2½ years, 3 years, 3½ years, 4 years, 4½ years, 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>1 week, 1 month, 3 months, 6 months, 1 year, 2 years, 3 years, 4 years, 5 years</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Patient satisfaction with communications by text message</measure>
    <time_frame>1 week, 1 month, 3 months, 6 months, 1 year, 2 years, 3 years, 4 years, 5 years</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">298</enrollment>
  <condition>Glaucoma</condition>
  <arm_group>
    <arm_group_label>Aurolab glaucoma drainage device</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Trabeculectomy with mitomycin-c</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Aurolab glaucoma drainage device</intervention_name>
    <description>Patients undergoing surgery will receive an implant</description>
    <arm_group_label>Aurolab glaucoma drainage device</arm_group_label>
    <other_name>AADI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Trabeculectomy with mitomycin-c</intervention_name>
    <description>Trabeculectomy surgery augmented by application of mitomycin C (0.4 mg/ml) to the sclera in the region of the trabeculectomy site for a period of exactly 3 minutes.</description>
    <arm_group_label>Trabeculectomy with mitomycin-c</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18 to 85 years, inclusive&#xD;
&#xD;
          -  Open angle glaucoma. Including primary open angle glaucoma, pseudoexfoliative and&#xD;
             pigmentary glaucoma&#xD;
&#xD;
          -  Intraocular pressure 18 - 40 mmHg on maximal tolerated or maximal affordable medical&#xD;
             therapy&#xD;
&#xD;
          -  Informed consent given and consent form signed.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unwilling or unable to give consent, unwilling to accept randomisation, or unable to&#xD;
             return for scheduled protocol visits&#xD;
&#xD;
          -  Pregnant or nursing women&#xD;
&#xD;
          -  No light perception vision&#xD;
&#xD;
          -  Previous incisional intraocular surgery, other than uncomplicated clear corneal&#xD;
             cataract surgery&#xD;
&#xD;
          -  Previous ocular laser in study eye&#xD;
&#xD;
          -  Iris neovascularisation or proliferative retinopathy&#xD;
&#xD;
          -  Primary angle closure or primary angle closure glaucoma&#xD;
&#xD;
          -  Iridocorneal endothelial syndrome or anterior segment dysgenesis&#xD;
&#xD;
          -  Epithelial or fibrous downgrowth&#xD;
&#xD;
          -  Aphakia&#xD;
&#xD;
          -  Chronic or recurrent uveitis&#xD;
&#xD;
          -  Steroid-induced glaucoma&#xD;
&#xD;
          -  Severe posterior blepharitis&#xD;
&#xD;
          -  Unwilling to discontinue contact lens use after surgery&#xD;
&#xD;
          -  Previous cyclodestructive procedure&#xD;
&#xD;
          -  Glaucoma secondary to penetrating keratoplasty, trauma, retinal disease/surgery or&#xD;
             neovascular disease&#xD;
&#xD;
          -  Conjunctival scarring from prior ocular surgery, trauma or cicatrizing disease&#xD;
             precluding a superior trabeculectomy&#xD;
&#xD;
          -  Need for glaucoma surgery combined with other ocular procedures (i.e. cataract&#xD;
             surgery, penetrating keratoplasty, or retinal surgery) or anticipated need for urgent&#xD;
             additional ocular surgery&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexander Spratt, MBBCh FRCOphth</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tema Christian Eye Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Keith Barton, MBBCh MD FRCP FRCOphth</last_name>
    <role>Study Chair</role>
    <affiliation>Moorfields Eye Hospital NHS Foundation Trust</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Donald L Budenz, MD MPH</last_name>
    <role>Study Chair</role>
    <affiliation>University of North Carolina, Chapel Hill</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alexander Spratt, MBBCh FRCOphth</last_name>
    <phone>+233549446981</phone>
    <email>mail@gptvt.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Tema Christian Eye Center</name>
      <address>
        <city>Tema</city>
        <country>Ghana</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Alexander Spratt, MBBCh FRCOphth</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Ghana</country>
  </location_countries>
  <link>
    <url>http://www.gptvt.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>March 2014</verification_date>
  <study_first_submitted>March 11, 2014</study_first_submitted>
  <study_first_submitted_qc>March 14, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 17, 2014</study_first_posted>
  <last_update_submitted>March 14, 2014</last_update_submitted>
  <last_update_submitted_qc>March 14, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 17, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tema Christian Eye Center</investigator_affiliation>
    <investigator_full_name>Alex Spratt</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitomycins</mesh_term>
    <mesh_term>Mitomycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

